Table 1. Summary characteristics of included trials.
|
TRIAL n MT/CON |
Journal | Year | Sites |
Median NIHSS MT/CON |
MT from symptom onset (hours) | Imaging modality for inclusion |
Proportion received IV thrombolytic therapy MT/CON |
Protocol mandated thrombectomy technique | Symptom onset to groin puncture (mins) | Attempt with any MT device | MT with stent retriever | MT with aspiration catheter | TICI 2b-3 at procedure end |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ESCAPE20 165/150 |
NEJM | 2015 | 22 sites, worldwide | 16 / 17 | ≤12 | NCCT + CTA | 72.7 / 78.7 | Retrievable stent recommended | 241◊ (176-359) | 91.5% 151/165 | 86.1% 130/151 | Not specified | 72.4% 113/156 |
|
EXTEND-IA21 35/35 |
NEJM | 2015 |
10 sites, AUS + NZ |
17 / 13 | <4.5 |
CTA + CT perfusion |
100 / 100 | Solitaire | 210 (166-251) | 77.1% 27/35 | 100% 27/27 | 0.0% 0/27 |
86.2 25/29 |
|
MR CLEAN22 233/267 |
NEJM | 2015 | 16 sites, Netherlands | 17 / 18 | ≤6 | CTA / MRA / DSA | 87.1 / 90.6 | Any CE marked or FDA approved device | 260 (210-313) | 81.9% 193/233 | 98.4% 190/193 | Not specified | 58.7% 115/196 |
|
REVASCAT23 103/103 |
NEJM | 2015 | 4 sites, Spain | 17 / 17 | ≤8 | CTA / MRA / DSA | 68.0 / 77.7 | Solitaire | 269 (201-340) | 95.1% 98/103 | 100% 98/98 | 0.0% 0/98 | 65.7% 67/102 |
|
SWIFT PRIME24 98/98 |
NEJM | 2015 |
39 sites, USA, Europe |
17 / 17 | ≤6 | CTA / MRA | 100 / 100 | Solitaire | 224 (165-275) | 89.0% 87/98 | 100% 87/87 | 0.0% 0/87 | 88.0% 73/83 |
|
THRACE18 204/208 |
Lancet Neurology | 2016 | 26 sites, France | 18 / 17 | <5 | CTA / MRA | 100 / 100 | Any CE marked device | 250 (210-290) | 68.6% 140/204 | 90.0% 126/140 | 20.7% 29/140 | 68.8% 95/138 |
|
THERAPY6 55/53 |
Stroke | 2016 |
36 sites, USA, Germany |
17 / 18 | Not specified | NCCT + CTA | 100 / 100 | Penumbra | 227 (184-263) | 81.8% 45/55 | 15.5% 7/45 | 95.6% 43/45 | 73.3% 33/45 |
|
PISTE7 33/32 |
J Neurol Neurosurg Psychiatry | 2017 |
10 sites, UK |
18 / 14 | ≤6 | CTA / MRA | 100 / 100 | Any CE marked device | 209 | 97.0% 32/33 | 68%§ | 32%§ | 86.7% 26/30 |
|
EASI19 40/37 |
J Neurorad | 2017 |
1 site, Canada |
18 / 20 | <6 | NCCT | 57.5 / 62.2 | Any approved stent retriever | 245 (105-580) | 75.0% 30/40 | 96.7% 29/30 | Not specified | 76.7% 23/30 |
|
DAWN9 107/99 |
NEJM | 2018 | 26 sites, worldwide | 17 / 17 | 6-24 |
CTA / MRA + dwMR / CT perfusion |
4.7 / 13.1 | Trevo | 768◊◊ (636-1002) | 98.1% 105/107 | 100% 105/105 | 0.0% 0/105 | 84.1% 90/107 |
|
DEFUSE310 92/90 |
NEJM | 2018 |
38 sites, USA |
16 / 16 | 6-16 |
CTA / MRA + dwMR / CT perfusion |
10.8 / 8.9 | Any FDA approved device | 688* | 97.8% 90/92 | 82.2% 74/90 | 27.8%** 25/90 | 75.8% 69/91 |
|
RESILIENT8 111/110 |
NEJM | 2020 | 12 sites, Brazil | 18 / 18 | ≤8 | CTA / MRA / DSA | 68.5 / 71.8 | Solitaire FR / Penumbra | 259* | 94.6% 105/111 | 68.6% 72/105 | 66.7% 70/105 | 82.0% 91/111 |
| Values indicate mean±SD, unless indicated as a median (IQR). ◊Time from stroke onset to reperfusion. ◊◊ Time since last known to be well to arterial puncture. §Proportion of patients undergoing thrombectomy procedure in which a stent retriever was used as the first device. *Derived value from available values. **Number of patients who underwent aspiration alone. CON: control arm; CTA: CT angiogram; DSA: digital subtraction angiography; dwMR: diffusion weighted magnetic resonance; INT: intervention arm; MRA: magnetic resonance angiography; MT: mechanical thrombectomy; NCCT: non-contrast computed tomography; NIHSS: National Institutes of Health Stroke Scale; TICI: Thrombolysis In Cerebral Infarction score | |||||||||||||